TY - JOUR
T1 - Statistical tools for dose individualization of mycophenolic acid and tacrolimus co-administered during the first month after renal transplantation
AU - Musuamba Tshinanu, Flora
AU - Mourad, Michel
AU - Haufroid, Vincent
AU - De Meyer, Martine
AU - Capron, Arnaud
AU - Delattre, Isabelle K.
AU - Verbeeck, Roger K.
AU - Wallemacq, Pierre
PY - 2013/5
Y1 - 2013/5
N2 - Aim: To predict simultaneously the area under the concentration-time curve during one dosing interval [AUC(0,12h)] for mycophenolic acid (MPA) and tacrolimus (TAC), when concomitantly used during the first month after transplantation, based on common blood samples. Methods: Data were from two different sources, real patient pharmacokinetic (PK) profiles from 65 renal transplant recipients and 9000 PK profiles simulated from previously published models on MPA or TAC in the first month after transplantation. Multiple linear regression (MLR) and Bayesian estimation using optimal samples were performed to predict MPA and TAC AUC(0,12h) based on two concentrations. Results: The following models were retained: AUC(0,12h) = 16.5 + 4.9 × C1.5 + 6.7 × C3.5 (r2 = 0.82, rRMSE = 9%, with simulations and r2 = 0.66, rRMSE = 24%, with observed data) and AUC(0,12h) = 24.3 + 5.9 × C1.5 + 12.2 × C3.5 (r2 = 0.94, rRMSE = 12.3%, with simulations r2 = 0.74, rRMSE = 15%, with observed data) for MPA and TAC, respectively. In addition, Bayesian estimators were developed including parameter values from final models and values of concentrations at 1.5 and 3.5h after dose. Good agreement was found between predicted and reference AUC(0,12h) values: r2 = 0.90, rRMSE = 13% and r2 = 0.97, rRMSE = 5% with simulations for MPA and TAC, respectively and r2 = 0.75, rRMSE = 11% and r2 = 0.83, rRMSE = 7% with observed data for MPA and TAC, respectively. Conclusion: Statistical tools were developed for simultaneous MPA and TAC therapeutic drug monitoring. They can be incorporated in computer programs for patient dose individualization.
AB - Aim: To predict simultaneously the area under the concentration-time curve during one dosing interval [AUC(0,12h)] for mycophenolic acid (MPA) and tacrolimus (TAC), when concomitantly used during the first month after transplantation, based on common blood samples. Methods: Data were from two different sources, real patient pharmacokinetic (PK) profiles from 65 renal transplant recipients and 9000 PK profiles simulated from previously published models on MPA or TAC in the first month after transplantation. Multiple linear regression (MLR) and Bayesian estimation using optimal samples were performed to predict MPA and TAC AUC(0,12h) based on two concentrations. Results: The following models were retained: AUC(0,12h) = 16.5 + 4.9 × C1.5 + 6.7 × C3.5 (r2 = 0.82, rRMSE = 9%, with simulations and r2 = 0.66, rRMSE = 24%, with observed data) and AUC(0,12h) = 24.3 + 5.9 × C1.5 + 12.2 × C3.5 (r2 = 0.94, rRMSE = 12.3%, with simulations r2 = 0.74, rRMSE = 15%, with observed data) for MPA and TAC, respectively. In addition, Bayesian estimators were developed including parameter values from final models and values of concentrations at 1.5 and 3.5h after dose. Good agreement was found between predicted and reference AUC(0,12h) values: r2 = 0.90, rRMSE = 13% and r2 = 0.97, rRMSE = 5% with simulations for MPA and TAC, respectively and r2 = 0.75, rRMSE = 11% and r2 = 0.83, rRMSE = 7% with observed data for MPA and TAC, respectively. Conclusion: Statistical tools were developed for simultaneous MPA and TAC therapeutic drug monitoring. They can be incorporated in computer programs for patient dose individualization.
KW - Bayesian estimators
KW - Dose individualization
KW - Multiple linear regression
KW - Mycophenolate
KW - Optimality
KW - Tacrolimus
UR - http://www.scopus.com/inward/record.url?scp=84876049583&partnerID=8YFLogxK
U2 - 10.1111/bcp.12007
DO - 10.1111/bcp.12007
M3 - Article
C2 - 23072565
AN - SCOPUS:84876049583
SN - 0306-5251
VL - 75
SP - 1277
EP - 1288
JO - British Journal of Clinical Pharmacology
JF - British Journal of Clinical Pharmacology
IS - 5
ER -